VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Receives Consensus Rating of “Reduce” from Brokerages

Shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN) have been given a consensus rating of “Reduce” by the five analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and four have issued a hold recommendation on the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $0.95.

Several equities analysts have recently issued reports on VTGN shares. Stifel Nicolaus cut VistaGen Therapeutics from a “buy” rating to a “hold” rating and set a $1.00 price objective for the company. in a report on Wednesday, December 17th. Wall Street Zen upgraded VistaGen Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, February 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of VistaGen Therapeutics in a report on Wednesday, January 21st. Jefferies Financial Group reaffirmed a “hold” rating and set a $0.90 price objective (down from $15.00) on shares of VistaGen Therapeutics in a research note on Wednesday, December 17th. Finally, William Blair reaffirmed a “market perform” rating on shares of VistaGen Therapeutics in a report on Wednesday, December 17th.

Institutional Investors Weigh In On VistaGen Therapeutics

Several hedge funds have recently modified their holdings of VTGN. Stempoint Capital LP grew its position in shares of VistaGen Therapeutics by 2.0% during the 2nd quarter. Stempoint Capital LP now owns 2,413,254 shares of the company’s stock valued at $4,827,000 after acquiring an additional 46,700 shares during the period. Geode Capital Management LLC boosted its position in VistaGen Therapeutics by 18.3% during the fourth quarter. Geode Capital Management LLC now owns 352,836 shares of the company’s stock worth $234,000 after purchasing an additional 54,556 shares in the last quarter. Luminus Management LLC acquired a new stake in VistaGen Therapeutics in the fourth quarter valued at approximately $232,000. Two Sigma Investments LP increased its position in shares of VistaGen Therapeutics by 223.5% in the third quarter. Two Sigma Investments LP now owns 289,409 shares of the company’s stock valued at $1,027,000 after buying an additional 199,958 shares in the last quarter. Finally, AdvisorShares Investments LLC raised its stake in shares of VistaGen Therapeutics by 20.9% during the 4th quarter. AdvisorShares Investments LLC now owns 250,188 shares of the company’s stock worth $166,000 after buying an additional 43,190 shares during the period. 78.39% of the stock is owned by hedge funds and other institutional investors.

VistaGen Therapeutics Stock Up 0.5%

Shares of NASDAQ:VTGN traded up $0.00 during midday trading on Monday, reaching $0.59. The company’s stock had a trading volume of 212,302 shares, compared to its average volume of 1,163,577. The stock has a fifty day moving average of $0.62 and a 200 day moving average of $2.64. VistaGen Therapeutics has a twelve month low of $0.43 and a twelve month high of $5.14. The firm has a market capitalization of $23.34 million, a PE ratio of -0.31 and a beta of 0.32.

VistaGen Therapeutics (NASDAQ:VTGN) last posted its earnings results on Thursday, February 12th. The company reported ($0.45) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.51) by $0.06. The business had revenue of $0.30 million for the quarter, compared to analyst estimates of $0.14 million. Sell-side analysts anticipate that VistaGen Therapeutics will post -1.77 earnings per share for the current fiscal year.

VistaGen Therapeutics Company Profile

VistaGen Therapeutics, Inc (NASDAQ:VTGN) is a clinical-stage biopharmaceutical company dedicated to the discovery and development of next-generation medicines for central nervous system disorders. Incorporated in Delaware in 1998 and headquartered in South San Francisco, California, VistaGen applies advanced human pluripotent stem cell technologies to accelerate drug candidate validation and optimization. The company’s core focus is on addressing unmet medical needs in major depressive disorder, neuropathic pain and dermatological conditions.

The company’s lead candidate, AV-101, is an oral prodrug designed to modulate glutamatergic neurotransmission via the N-methyl-D-aspartate (NMDA) receptor pathway, with clinical programs targeting major depressive disorder and neuropathic pain.